Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2021 · 10-Q
Revenue—
Net Income-$1.56M-$1.56MN/M vs Q3 2020 EPS Diluted$0.00$0.00N/M vs Q3 2020 Operating Income-$1,808,962N/M Operating Cash Flowderived-$900,685N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 22, 2021 · 53 d after period end